C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Cora N. Sternberg,Fred Saad,J.N. Graff,Avivit Peer,Ulka N. Vaishampayan,E. Leung,Eli Rosenbaum,Howard Gurney,Richard J. Epstein,Ian D. Davis,B. Wu,L. Trandafir,Volker Wagner,Maha Hussain +13 more
TL;DR: The standard-dose schedule for radium-223 high-dose or extended-schedule regimens remained one of the standard therapies for patients with symptomatic mCRPC and could not be implemented in a large proportion of patients due to disease progression.
Journal ArticleDOI
Impact of Enzalutamide, An Androgen Receptor Signaling Inhibitor, on Time to First Skeletal Related Event (SRE) and Pain in the Phase 3 Affirm Study
Karim Fizazi,Howard I. Scher,Fred Saad,Cora N. Sternberg,Kurt Miller,Peter F.A. Mulders,Kim N. Chi,Ethan Basch,M. Hirmand,J.S. de Bono +9 more
TL;DR: In the AFFIRM phase 3 trial, enzalutamide significantly delayed the time to first SRE and had a consistently favorable and significant impact on measures of pain vs placebo.
Journal ArticleDOI
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
Cora N. Sternberg,Robert J. Motzer,Thomas E. Hutson,Toni K. Choueiri,Christian Kollmannsberger,Georg A. Bjarnason,Paul Nathan,Camillo Porta,Viktor Grünwald,Luca Dezzani,Jackie Han,Nizar M. Tannir +11 more
TL;DR: Dose modifications when required because of AEs were associated with improved efficacy, suggesting that AEs might be used as a surrogate marker of adequate dosing for individual patients.
Journal ArticleDOI
Phase II Trial of Trimetrexate in Patients with Advanced Renal Cell Carcinoma
Cora N. Sternberg,Alan Yagoda,Howard I. Scher,George J. Bosl,D. David Dershaw,Kim Rosado,Collette Houston,Richard Rosenbluth,Vincent Vinciguerra,Bruce Boselli +9 more
Journal ArticleDOI
Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).
Yuan Liu,Hai T. Tran,Y. Lin,Anne-Marie Martin,Amado J. Zurita,Cora N. Sternberg,Rafael G. Amado,Lini Pandite,John V. Heymach,Veg Team +9 more
TL;DR: This study validated HGF, IL-8, OPN, and TIMP-1 as markers associated with clinical benefit with PAZO treatment and confirmed IL-6 was both a prognostic marker and predictive marker for pazopanib therapy.